Cytosorbents (CTSO) Operating Income (QoQ) (2011 - 2026)
Cytosorbents (CTSO) Operating Income (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.34% |
| Mar 31, 2026 | 30.58% |
| Dec 31, 2025 | -53.21% |
| Sep 30, 2025 | 20.83% |
| Jun 30, 2025 | 7.02% |
| Mar 31, 2025 | -14.52% |
| Dec 31, 2024 | 29.71% |
| Sep 30, 2024 | -35.29% |
| Jun 30, 2024 | 23.33% |
| Mar 31, 2024 | 50.51% |
| Dec 31, 2023 | -28.00% |
| Sep 30, 2023 | -12.06% |
| Jun 30, 2023 | 16.88% |
| Mar 31, 2023 | -24.15% |
| Dec 31, 2022 | 29.51% |
| Sep 30, 2022 | -7.90% |
| Jun 30, 2022 | -7.26% |
| Mar 31, 2022 | 18.52% |
| Dec 31, 2021 | -76.87% |
| Sep 30, 2021 | -9.77% |